https://mindmedicinelaw.com/briefing/far-overhaul-implications-for-psychedelic-r-d-contracting-in-the-u-s-20260918-42794The Psychedelic Journalen2026-09-18T15:06:20.284332+00:00FAR Overhaul: Implications for Psychedelic R&D Contracting in the U.S.federal acquisition regulation, psychedelic research funding, federal r&d contracting, policy overhaul, research compliance, federal procurement, contract eligibility, administrative barriers, executive order 14275, us federal agencieshttps://mindmedicinelaw.com/briefing/emerging-psychedelic-therapies-for-treatment-resistant-depression-clinical-evide-20260917-42856The Psychedelic Journalen2026-09-18T15:08:48.505996+00:00Emerging Psychedelic Therapies for Treatment-Resistant Depression: Clinical Evidence and Integration Challengestreatment-resistant depression, psilocybin, psychedelic-assisted therapy, clinical trials, neuromodulation, ketamine, regulatory policy, mental health innovation, FDA breakthrough therapy, implementation challengeshttps://mindmedicinelaw.com/briefing/high-ventilation-breathwork-as-a-psychedelic-model-clinical-and-policy-implicati-20260917-42822The Psychedelic Journalen2026-09-18T15:06:36.067909+00:00High Ventilation Breathwork as a Psychedelic Model: Clinical and Policy Implicationshigh ventilation breathwork, psychedelic-like states, non-pharmacological models, clinical trial design, internalizing disorders, psychedelic therapy mechanisms, regulatory barriers, contraindications, mental health researchhttps://mindmedicinelaw.com/briefing/fda-hearing-reveals-deep-divisions-on-psychedelic-medicine-approval-20260917-42942The Psychedelic Journalen2026-09-18T15:05:46.543747+00:00FDA Hearing Reveals Deep Divisions on Psychedelic Medicine Approvalfda hearing, psychedelic medicine, regulatory approval, clinical trials, policy debate, safety and efficacy, mdma, psilocybin, patient access, insurance coveragehttps://mindmedicinelaw.com/briefing/fda-holds-landmark-public-hearing-on-psychedelics-policy-2026-20260917-42778The Psychedelic Journalen2026-09-17T22:04:29.957310+00:00FDA Holds Landmark Public Hearing on Psychedelics Policy (2026)fda psychedelics hearing, maps, psychedelic regulation, clinical trial policy, us drug policy, psychedelic research, mdma, psilocybin, federal law, drug approval processhttps://mindmedicinelaw.com/briefing/fda-engages-on-psychedelic-therapy-policy-and-movement-tensions-20260917-42621The Psychedelic Journalen2026-09-17T15:08:41.603058+00:00FDA Engages on Psychedelic Therapy: Policy and Movement Tensionsfda psychedelic therapy, psychedelic regulation, clinical trials, policy guidance, access and equity, movement priorities, drug approval process, mental health innovation, risk managementhttps://mindmedicinelaw.com/briefing/clearmind-medicine-s-fda-testimony-psychedelic-policy-and-meai-trial-insights-20260917-42620The Psychedelic Journalen2026-09-17T15:05:32.330149+00:00Clearmind Medicine's FDA Testimony: Psychedelic Policy and MEAI Trial Insightsfda psychedelic hearing, clearmind medicine, meai clinical trial, patient access, psychedelic policy, novel psychoactive compounds, regulatory engagement, safety and efficacy data, clinical trial designhttps://mindmedicinelaw.com/briefing/psychopharmacology-access-gaps-in-brazil-s-sus-policy-and-research-implications-20260916-42827The Psychedelic Journalen2026-09-18T15:08:59.291408+00:00Psychopharmacology Access Gaps in Brazil’s SUS: Policy and Research Implicationsbrazil mental health policy, sus drug access, rename essential medicines, psychopharmacology disparities, esketamine access brazil, public health system, psychiatric drug formulary, telepsychiatry brazil, treatment-resistant depression, health technology assessmenthttps://mindmedicinelaw.com/briefing/psilocybin-therapy-in-trd-with-cluster-b-personality-disorders-first-clinical-tr-20260916-42826The Psychedelic Journalen2026-09-18T15:07:00.228155+00:00Psilocybin Therapy in TRD with Cluster B Personality Disorders: First Clinical Trial Findingspsilocybin-assisted psychotherapy, treatment-resistant depression, cluster B personality disorders, clinical trial, safety and tolerability, suicidal ideation, trial design, regulatory implications, psychedelic researchhttps://mindmedicinelaw.com/briefing/psychedelics-for-treatment-resistant-depression-clinical-evidence-and-outlook-20-20260916-42844The Psychedelic Journalen2026-09-18T15:06:03.470232+00:00Psychedelics for Treatment-Resistant Depression: Clinical Evidence and Outlook (2026 Review)psilocybin, treatment-resistant depression, clinical trials, psychedelic therapy, ayahuasca, DMT, safety and efficacy, trial methodology, blinding challenges, regulatory outlookhttps://mindmedicinelaw.com/briefing/psychedelics-and-traumatic-brain-injury-new-qualitative-evidence-from-participan-20260916-42509The Psychedelic Journalen2026-09-17T15:09:04.040040+00:00Psychedelics and Traumatic Brain Injury: New Qualitative Evidence from Participant Narrativespsychedelics, traumatic brain injury, tbi recovery, qualitative research, neurorehabilitation, clinical trials, subjective outcomes, mental health, policy gapshttps://mindmedicinelaw.com/briefing/preparedness-and-risk-in-oregon-psilocybin-consult-patients-20260916-42510The Psychedelic Journalen2026-09-17T15:07:31.219583+00:00Preparedness and Risk in Oregon Psilocybin Consult Patientspsilocybin, oregon, psychedelic consultation, risk reduction, trauma prevalence, clinical preparedness, psychedelic policy, psychiatric care, regulated accesshttps://mindmedicinelaw.com/briefing/psilocybin-clinical-trial-reduces-depression-alters-self-concept-20260916-42547The Psychedelic Journalen2026-09-17T15:06:48.075944+00:00Psilocybin Clinical Trial Reduces Depression, Alters Self-Conceptpsilocybin, major depressive disorder, clinical trial, self-concept, neuroimaging, fMRI, placebo-controlled, psychedelic therapy, regulatory sciencehttps://mindmedicinelaw.com/briefing/psilocybin-trial-links-self-concept-shifts-to-depression-relief-20260916-42546The Psychedelic Journalen2026-09-17T15:05:59.364463+00:00Psilocybin Trial Links Self-Concept Shifts to Depression Reliefpsilocybin, major depressive disorder, self-concept, clinical trial, neuroimaging, self-referential processing, caudate activation, psychedelic therapy, regulatory pathwayshttps://mindmedicinelaw.com/briefing/improving-psychedelic-clinical-trials-methodology-challenges-and-next-steps-20260916-42463The Psychedelic Journalen2026-09-16T22:07:22.935633+00:00Improving Psychedelic Clinical Trials: Methodology Challenges and Next Stepspsychedelic clinical trials, blinding in trials, expectancy effects, trial reproducibility, FDA guidance, regulatory standards, methodological rigor, psychedelic research, clinical trial design, public health policyhttps://mindmedicinelaw.com/briefing/fda-poised-to-approve-psychedelic-therapy-for-trd-implications-and-next-steps-20260916-42462The Psychedelic Journalen2026-09-16T22:05:27.144886+00:00FDA Poised to Approve Psychedelic Therapy for TRD: Implications and Next Stepsfda approval, psilocybin therapy, treatment-resistant depression, compass pathways, clinical trials, policy implications, insurance coverage, psychedelic medicine, risk evaluation, mental health innovationhttps://mindmedicinelaw.com/briefing/colorado-psychedelic-decriminalization-policy-limits-and-next-steps-20260915-42779The Psychedelic Journalen2026-09-17T22:04:46.054944+00:00Colorado Psychedelic Decriminalization: Policy, Limits, and Next Stepscolorado psychedelics policy, decriminalization, psilocybin law, state drug reform, research barriers, federal-state conflict, public health risks, therapeutic facilitation, law enforcement, regulatory uncertaintyhttps://mindmedicinelaw.com/briefing/blood-neurofilament-light-chain-as-a-marker-in-substance-using-populations-20260915-42529The Psychedelic Journalen2026-09-17T15:09:40.984117+00:00Blood Neurofilament Light Chain as a Marker in Substance-Using Populationsneurofilament light chain, nfl biomarker, substance use neurotoxicity, psychoactive substances, meta-analysis, clinical trials, public health policy, alcohol neurotoxicity, biomarker specificity, sex differences in neurotoxicityhttps://mindmedicinelaw.com/briefing/mri-study-reveals-brain-circuit-differences-in-gambling-disorder-20260915-42515The Psychedelic Journalen2026-09-17T15:09:23.116135+00:00MRI Study Reveals Brain Circuit Differences in Gambling Disordergambling disorder, mri, addiction neuroscience, prefrontal cortex, limbic system, striatal circuits, psychedelic therapy, functional connectivity, grey matter volume, clinical trialshttps://mindmedicinelaw.com/briefing/trump-s-public-reference-to-psychedelic-therapies-u-s-policy-implications-20260915-42622The Psychedelic Journalen2026-09-17T15:07:53.825173+00:00Trump’s Public Reference to Psychedelic Therapies: U.S. Policy Implicationspsychedelic policy, trump remarks, us federal law, fda breakthrough therapy, clinical trials, public opinion, state-level reform, mdma, psilocybin, regulatory riskhttps://mindmedicinelaw.com/briefing/music-as-a-contextual-variable-in-psychedelic-therapy-trials-20260915-42351The Psychedelic Journalen2026-09-16T22:07:45.991429+00:00Music as a Contextual Variable in Psychedelic Therapy Trialspsychedelic-assisted psychotherapy, music in therapy, clinical trial design, contextual factors, complex interventions, regulatory standards, trial reproducibility, adverse events, functional standardizationhttps://mindmedicinelaw.com/briefing/neurocognitive-model-psychedelics-and-hippocampal-reset-in-anxiety-relief-20260915-42350The Psychedelic Journalen2026-09-16T22:06:42.669265+00:00Neurocognitive Model: Psychedelics and Hippocampal Reset in Anxiety Reliefpsychedelics, anxiety disorders, hippocampal reset, neurocognitive model, psilocybin, clinical trial design, biomarkers, cortical plasticity, regulatory policyhttps://mindmedicinelaw.com/briefing/lived-experience-as-evidence-in-psychedelic-public-health-policy-20260915-42352The Psychedelic Journalen2026-09-16T22:06:26.065111+00:00Lived Experience as Evidence in Psychedelic Public Health Policylived experience, psychedelic public health, clinical trials, policy development, aftercare, systems-relevant evidence, regulatory oversight, patient safety, program evaluationhttps://mindmedicinelaw.com/briefing/psilocybin-ayahuasca-for-trd-evidence-ethics-and-research-gaps-20260915-42353The Psychedelic Journalen2026-09-16T22:06:05.582463+00:00Psilocybin & Ayahuasca for TRD: Evidence, Ethics, and Research Gapspsilocybin, ayahuasca, treatment-resistant depression, clinical trial design, ethical challenges, blinding, informed consent, psychedelic-assisted therapy, regulatory science, methodological limitationshttps://mindmedicinelaw.com/briefing/psychedelic-therapy-regulation-australia-brazil-usa-compared-20260914-42848The Psychedelic Journalen2026-09-18T15:07:22.666394+00:00Psychedelic Therapy Regulation: Australia, Brazil, USA Comparedpsychedelic therapy regulation, australia mdma psilocybin, brazil ayahuasca policy, usa psychedelic law, patient safety, ethical oversight, indigenous rights, clinical access, schedule 1 substances, policy comparisonhttps://mindmedicinelaw.com/briefing/prenatal-dexamethasone-and-neurogenesis-epigenetic-risks-in-psychiatric-health-20260914-42390The Psychedelic Journalen2026-09-16T22:08:30.483853+00:00Prenatal Dexamethasone and Neurogenesis: Epigenetic Risks in Psychiatric Healthprenatal dexamethasone, hippocampal neurogenesis, epigenetic regulation, psychiatric risk, glucocorticoid exposure, PI3K-Akt-mTOR pathway, psychedelic therapy, depression-like behaviors, neurodevelopment, public health policyhttps://mindmedicinelaw.com/briefing/pharmacogenetics-and-psychotropic-response-implications-for-psychedelic-psychiat-20260914-42399The Psychedelic Journalen2026-09-16T22:08:07.882523+00:00Pharmacogenetics and Psychotropic Response: Implications for Psychedelic Psychiatrypharmacogenetics, cyp2d6, cyp2c19, psychedelic therapy, personalized medicine, clinical trial design, phenoconversion, adverse events, precision psychiatryhttps://mindmedicinelaw.com/briefing/5-ht2a-receptor-mechanisms-and-policy-implications-in-psychedelic-research-20260914-42354The Psychedelic Journalen2026-09-16T22:07:02.123784+00:005-HT2A Receptor: Mechanisms and Policy Implications in Psychedelic Research5-ht2a receptor, psychedelics, mechanism of action, neuroplasticity, clinical trials, mental disorders, policy implications, biomarkers, regulatory sciencehttps://mindmedicinelaw.com/briefing/constraint-based-consciousness-model-5-meo-dmt-anchored-predictions-20260913-42888The Psychedelic Journalen2026-09-18T15:08:34.522504+00:00Constraint-Based Consciousness Model: 5-MeO-DMT Anchored Predictionsconstraint-based consciousness, 5-meo-dmt research, psychedelic neuroscience, neural correlates of consciousness, clinical trial design, eeg biomarkers, amnesia and awareness, field-limiting transducer, pharmacological dissociation, consciousness substratehttps://mindmedicinelaw.com/briefing/empirical-refutation-and-correction-of-thermodynamic-markers-in-sleep-and-psyche-20260913-42889The Psychedelic Journalen2026-09-18T15:07:39.324012+00:00Empirical Refutation and Correction of Thermodynamic Markers in Sleep and Psychedelicsthermodynamic marker, consciousness biomarker, sleep neuroscience, psychedelic brain states, integrated information, biomarker validation, neural invariants, methodological rigorhttps://mindmedicinelaw.com/briefing/structured-at-home-ketamine-protocol-clinical-and-policy-implications-20260911-42395The Psychedelic Journalen2026-09-16T22:05:45.663309+00:00Structured At-Home Ketamine Protocol: Clinical and Policy Implicationsat-home ketamine, racemic ketamine protocol, psychiatric treatment, decentralized therapy, route-specific dosing, telemedicine, regulatory standards, patient safety, clinical best practiceshttps://mindmedicinelaw.com/briefing/non-response-to-ketamine-in-trd-clinical-correlates-and-implications-20260910-42568The Psychedelic Journalen2026-09-17T15:10:03.385466+00:00Non-Response to Ketamine in TRD: Clinical Correlates and Implicationsketamine non-responders, treatment-resistant depression, life engagement, clinical trial design, psychedelic-assisted therapy, patient selection, FDA guidance, biomarkers, anhedonia, psychiatric comorbidity